The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma

The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma

Background: Adjuvant chemotherapy (ACT) remains the current first-line systemic treatment option for patients with KRAS-mutated lung adenocarcinoma (LUAD), but the response is not effective. The prognosis of ACT in patients with KRAS mutations in stage I LUAD has not yet been effectively explored. M...

Full description

Saved in:
Bibliographic Details
Main Authors: Shangshang Ma, Kun Li, Rangrang Wang, Jiayi Qian, Yongfei Fan, Xichun Qin, Mingjun Li, Leilei Wu
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Clinical Surgical Oncology
Subjects:
lung adenocarcinoma
KRAS mutation
adjuvant chemotherapy
Prognosis
Co-mutation
Online Access:http://www.sciencedirect.com/science/article/pii/S2773160X24000370
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items